Article Text

Download PDFPDF
Efficacy of intra-articular bevacizumab for relapsing diffuse-type giant cell tumour
  1. M J Nissen1,
  2. A Boucher2,
  3. L Brulhart3,
  4. J Menetrey4,
  5. C Gabay1
  1. 1 Division of Rheumatology, Geneva University Hospital, Geneva, Switzerland
  2. 2 Division of Medicine, Catholic University of Louvain, Brussels, Belgium
  3. 3 Division of Rheumatology, Neuchatel Hospital, Neuchatel, Switzerland
  4. 4 Division of Orthopedic Surgery, Geneva University Hospital, Geneva, Switzerland
  1. Correspondence to Dr Michael J Nissen, Division of Rheumatology, Geneva University Hospital, 26 Avenue Beau Sejour, Geneva 1211, Switzerland; michael.j.nissen{at}

Statistics from

Diffuse-type giant cell tumours (GCT), also known as pigmented villonodular synovitis, are characterised by synovial hypertrophy that affects one or several joints, bursas or tendon sheaths, especially in young adults.1 GCT are generally treated by surgical synovectomy.1 ,2 However, the recurrence rate is high, with figures of up to 55%.3 Adjuvant therapies exist, such as external beam radiotherapy (EBM) or intra-articular injection of radiopharmaceuticals (eg, yttrium-90).46 Nevertheless, outcomes remain suboptimal and new management options are required. We describe herein the use of bevacizumab, a humanised monoclonal antivascular endothelial growth factor (VEGF) antibody, as an alternative therapy in a case of severe and refractory diffuse-type GCT.

A 24-year-old man without prior past medical history consulted for painful knee swelling. Arthroscopy with biopsy was performed and the …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.